Company intelligence / Profile preview

Ascendia Pharmaceutical Solutions

North Brunswick, New Jersey, United States

Ownership: Private
Development stage: Other

Overview

Ascendia Pharmaceutical Solutions specializes in providing formulation and manufacturing platforms for difficult-to-formulate drugs, including a novel nanoemulsion IV clopidogrel (developed with AcuteBio, IND-cleared in 2023), with clinical programs spanning from pre-clinical through Phase 3 and commercial supply[4][6].

Therapeutic areas: OncologyOphthalmologyCardiovascular
Modalities: Small moleculeBiologicGene therapyLipid nanoparticle delivery therapyNanoparticleNanoemulsion
Industry: Drug Discovery Services

Partnerships

AcuteBio (clopidogrel IV nanoemulsion and dry eye disease development)[4]Multiple biopharma and pharma companies as CDMO partners

Beyond the preview

Go deeper on Ascendia Pharmaceutical Solutions.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Ascendia Pharmaceutical Solutions.

Explore the full profile